Table 1.
Weighted prevalence and adjusted prevalence ratios (aPRs) of hypertension measures by QuantiFERON-TB Gold In-Tube status among US adults, NHANES 2011–2012
| Hypertension measures | Weighted prevalence of hypertension, % (95%CI) | ||||
| Total N=4989 |
Among QFT (−) 94.3 (93.3, 95.3) |
Among QFT (+) 5.7 (4.7, 6.7) |
Prevalence difference* percentage point (95%CI) |
aPR† (95% CI) | |
| Primary study outcome | |||||
| Any hypertension indication‡ (n=2580/4989) | 48.9 (45.2, 52.7) | 48.3 (44.5, 52.1) | 58.5 (52.4, 64.5) | 10.2 (5.0 to 15.4) | 1.01 (0.97 to 1.06) |
| Measured blood pressure | |||||
| Hypertension§ (n=1885/4989) | 35.0 (32.3, 37.6) | 34.5 (31.8, 37.2) | 43.2 (36.4, 49.9) | 8.7 (1.9 to 15.5) | 1.04 (0.97 to 1.12) |
| Stage one hypertension¶ (n=1273) | 24.5 (22.4, 26.7) | 24.2 (21.9, 26.5) | 30.1 (22.4, 37.9) | 5.9 (−2.3 to 14.2) | 1.13 (0.99 to 1.29) |
| Stage two hypertension** (n=612) | 10.4 (9.1, 11.8) | 10.3 (8.9, 11.7) | 13.0 (9.1, 17.0) | 2.8 (−1.3 to 6.8) | 0.88 (0.75 to 1.02) |
| Hypertension diagnosis | |||||
| Previously diagnosed hypertension†† (n=1711) | 30.8 (27.7, 33.9) | 30.3 (27.1, 33.6) | 38.3 (33.6, 43.1) | 8.0 (2.4 to 13.6) | 0.97 (0.90 to 1.04) |
| Current use of antihypertension medication‡‡ (n=1276) | 86.9 (83.7, 90.1) | 86.3 (82.7, 89.9) | 94.7 (90.9, 98.4) | 8.4 (2.3 to 14.4) | 1.13 (1.02 to 1.09) |
| Undiagnosed hypertension§§ (n=869) | 18.1 (16.1, 20.2) | 18.0 (15.8, 20.2) | 20.2 (14.0, 26.4) | 2.2 (−4.5 to 8.9) | 1.08 (0.91 to 1.28) |
Bold indicates that the finding is significant at α=0.05.
This table shows the prevalence of select hypertension measures in the overall adult cohort of NHANES 2011–2012 as well as stratified by their tuberculosis infection status. The crude measure of association was expressed as prevalence difference, while the adjusted measure of association was expressed as prevalence ratio.
*Mean/prevalence difference was calculated by setting those without TBI (ie, QFT negative) as the referent group.
†Model was adjusted for age, sex, race, education attainment level, country of birth, type 2 diabetes mellitus, body mass index and smoking.
‡Systolic ≥130 mm Hg and/or diastolic ≥80 mm Hg or self-reported previous diagnosis of high blood pressure by health providers or use of antihypertensive medications.
§Including stage 1 and 2 hypertensions (ie, systolic ≥130 mm Hg or diastolic ≥80 mm Hg).
¶Systolic 130–139 mm Hg or diastolic 80–89 mm Hg.
**Systolic ≥140 mm Hg or diastolic ≥90 mm Hg.
††Survey participants answered ‘yes’ to the question ‘(have you/has SP) ever been told by a doctor or other health professional that (you/s/he) had hypertension, also called high blood pressure?’.
‡‡Among those who answered ‘yes’ to ‘because of (your/SP’s) (high blood pressure/hypertension), (have you, has s/he) ever been told to take prescribed medicine?’, survey participants also answered ‘yes’ to the question ‘(are you/is SP) now taking prescribed medicine (for high blood pressure/hypertension)?’.
§§Elevated blood pressure levels (systolic ≥130 mm Hg or diastolic ≥80 mm Hg) with no prior diagnosis of hypertension by healthcare providers.
aPRs, adjusted prevalence ratios; NHANES, National Health and Nutrition Examination Survey; QFT, QuantiFERON-TB.